CorMedix Inc (NASDAQ:CRMD – Get Free Report) has received an average rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $15.22.
CRMD has been the topic of a number of recent research reports. UBS Group set a $19.00 target price on CorMedix in a report on Tuesday, November 10th. Oppenheimer reiterated an “outperform” rating and set a $13.00 price target (down from $15.00) on shares of CorMedix in a report on Friday, November 13th. Citigroup reiterated a “market outperform” rating on shares of CorMedix in a report on Tuesday, November 10th. Weiss Ratings lowered CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, November 10th. Finally, Needham & Company LLC raised their price objective on CorMedix from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th.
Check Out Our Latest Stock Analysis on CorMedix
Insider Activity
Hedge Funds Weigh In On CorMedix
Hedge funds and other institutional investors have recently modified their holdings of the business. American Century Companies Inc. increased its position in shares of CorMedix by 688.5% during the 3rd quarter. American Century Companies Inc. now owns 2,722,920 shares of the company’s stock valued at $20,966,000 after purchasing an additional 2,377,579 shares during the last quarter. Kestra Advisory Services LLC boosted its holdings in shares of CorMedix by 38.6% in the 3rd quarter. Kestra Advisory Services LLC now owns 17,950 shares of the company’s stock worth $138,000 after buying an additional 5,000 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in shares of CorMedix in the 3rd quarter worth about $196,000. Goldman Sachs Group Inc. boosted its holdings in shares of CorMedix by 167.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company’s stock worth $9,620,000 after buying an additional 782,989 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in CorMedix during the third quarter valued at about $332,000. Hedge funds and other institutional investors own 34.18% of the company’s stock.
CorMedix Stock Up 3.7%
Shares of NASDAQ CRMD opened at $5.27 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.43 and a quick ratio of 2.36. The company has a 50-day moving average price of $6.86 and a 200-day moving average price of $7.49. The stock has a market capitalization of $419.18 million, a P/E ratio of 7.64, a P/E/G ratio of 1.21 and a beta of 1.48. CorMedix has a 1 year low of $4.47 and a 1 year high of $13.02.
CorMedix (NASDAQ:CRMD – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $54.52 million during the quarter, compared to the consensus estimate of $51.76 million. CorMedix had a net margin of 15.49% and a return on equity of 26.70%. On average, equities research analysts forecast that CorMedix will post 0.44 EPS for the current fiscal year.
CorMedix Company Profile
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Featured Stories
- Five stocks we like better than CorMedix
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
